Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 2767Carcinoma, Non-Small-Cell Lung 2265Prostatic Neoplasms 1427Colorectal Neoplasms 1295Neoplasms 1260Multiple Myeloma 1086Lung Neoplasms 1049Neoplasm Metastasis 995Leukemia, Myeloid, Acute 985Lymphoma 900Melanoma 864Pancreatic Neoplasms 818Ovarian Neoplasms 805Carcinoma, Hepatocellular 782Stomach Neoplasms 753Recurrence 753Leukemia 733Lymphoma, Non-Hodgkin 684Leukemia, Lymphocytic, Chronic, B-Cell 665Squamous Cell Carcinoma of Head and Neck 618Lymphoma, Large B-Cell, Diffuse 617Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Head and Neck Neoplasms 598Brain Neoplasms 593Carcinoma, Renal Cell 587Glioblastoma 573Rectal Neoplasms 565Sarcoma 523Myelodysplastic Syndromes 522Lymphoma, Follicular 516

Interventions

trifluridine tipiracil drug combination 1berzosertib 1Trifluridine 1Taxes 1Ramucirumab 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Irinotecan 1Endoscopy 1Endoscopic Mucosal Resection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Clinical Stage III Gastric Cancer AJCC v8 × Clear all
NCT03641313 2026-04-13

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
17 enrolled 14 charts
Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

NCT04660760 2024-04-01

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Academic and Community Cancer Research United

Phase 2 Unknown
116 enrolled
Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡